A disease risk index for patients undergoing allogeneic stem cell transplantation

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho, John Koreth, Edwin P. Alyea, Jerome Ritz, Mohamed L. Sorror, Stephanie J. Lee, H.

Joachim Deeg, Barry E. Storer, Frederick R. Appelbaum, Joseph H. Antin, Robert J. Soiffer, and Haesook T. Kim

BloodVolume 120(4):905-913

July 26, 2012

©2012 by American Society of Hematology

OS after HSCT stratified by disease/status group and conditioning intensity.

Philippe Armand et al. Blood 2012;120:905-913

©2012 by American Society of Hematology

Outcomes of HSCT stratified by overall disease/status risk group.

Philippe Armand et al. Blood 2012;120:905-913

©2012 by American Society of Hematology

Outcomes of patients in the validation cohort stratified by disease/status risk group.

Philippe Armand et al. Blood 2012;120:905-913

©2012 by American Society of Hematology